CA3296584A1 - Compounds for the delivery of granulin across the blood brain barrier - Google Patents

Compounds for the delivery of granulin across the blood brain barrier

Info

Publication number
CA3296584A1
CA3296584A1 CA3296584A CA3296584A CA3296584A1 CA 3296584 A1 CA3296584 A1 CA 3296584A1 CA 3296584 A CA3296584 A CA 3296584A CA 3296584 A CA3296584 A CA 3296584A CA 3296584 A1 CA3296584 A1 CA 3296584A1
Authority
CA
Canada
Prior art keywords
granulin
delivery
compounds
brain barrier
blood brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3296584A
Other languages
French (fr)
Inventor
Alberto Alvarado
Forest H. ANDREWS
David Albert DRIVER
Ross Edward Fellows
Karen Jean Froning
Daniel Scott Girard
Petra Verdino
Yaming Wang
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA3296584A1 publication Critical patent/CA3296584A1/en
Pending legal-status Critical Current

Links

CA3296584A 2023-06-21 2024-06-18 Compounds for the delivery of granulin across the blood brain barrier Pending CA3296584A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63/509,352 2023-06-21

Publications (1)

Publication Number Publication Date
CA3296584A1 true CA3296584A1 (en) 2024-12-26

Family

ID=

Similar Documents

Publication Publication Date Title
IL325365A (en) Compounds for the delivery of granulin across the blood brain barrier
EP3986392A4 (en) Compounds for treatment of pd-l1 diseases
EP4153597A4 (en) Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
EP4155294A4 (en) Compound for preventing or treating lipid metabolism-related diseases
AU2024216821A1 (en) Rifabutin analogs for the treatment of bacterial diseases
CA3266446A1 (en) Novel compounds for the diagnosis of tdp-43 proteinopathies
CA3266876A1 (en) Rifabutin analogs for the treatment of disease
CA3296584A1 (en) Compounds for the delivery of granulin across the blood brain barrier
AU2022208045A9 (en) Active delivery of radiotracers across the blood brain barrier
EP4277663A4 (en) Active delivery of radiotracers across the blood brain barrier
EP3747435A4 (en) Pharmaceutical composition for preventing or treating diabetes complications comprising novel chrysin derivative compound as active ingredient
CN309880092S (en) Medical syringe
CA3298663A1 (en) Pharmaceutical compounds
CA3270489A1 (en) Compounds for use as medicaments
AU2023900260A0 (en) Compounds for the treatment of viruses
HK40081993A (en) Compounds for the treatment of covid-19
HK40113111A (en) Pharmaceutical composition comprising biopharmaceutical drug compounds
HK40130315A (en) Therapeutic compounds
HK40120680A (en) Methylene blue containing compounds for the treatment of methaemoglobinaemia
HK40052948A (en) Pharmaceutical compounds for the treatment of complement factor d medical disorders
CA3292803A1 (en) Naphthyridinone derivatives for the treatment of a disease or disorder
EM85639510006S (en) Injectors for medical purposes (part of -)
EM85639510003S (en) Injectors for medical purposes (part of -)
EM85639510005S (en) Injectors for medical purposes (part of -)
EM85639510004S (en) Injectors for medical purposes (part of -)